Wilson Sonsini Goodrich & Rosati is the premier legal advisor to technology, life sciences, and other growth enterprises worldwide. We represent companies at every stage of development, from entrepreneurial start-ups to multibillion-dollar global corporations, as well as the venture firms, private equity firms, and investment banks that finance and advise them. The firm’s broad range of services and practice areas are focused on addressing the principal challenges faced by the management, boards of directors, shareholders, and in-house counsel of our clients.
The firm is nationally recognized for providing high-quality services to address the legal solutions required by its enterprise and financial institution clients. Our services include corporate law and governance, public and private offerings of equity and debt securities, mergers and acquisitions, securities class action litigation, intellectual property litigation, antitrust counseling and litigation, joint ventures and strategic alliances, technology licensing and other intellectual property transactions, tax, and employee benefits and employment law, among other areas. Our distinguished international roster of clients span a wide variety of industries, including information technology, life sciences, energy and clean technology, media and entertainment, communications, retail, and financial services.
Jefferies provides insight, expertise and execution to investors, companies and government entities. We offer deep sector expertise across a full range of products and services in investment banking, equities, fixed income and wealth management in the Americas, Europe and the Middle East and Asia. As one of the largest global healthcare investment banking team, we have more than 100 healthcare bankers worldwide covering over 780 corporate clients. Jefferies Healthcare Team has a strong track record in transacting with Chinese healthcare companies in strong cross-border capabilities that connect Chinese buyers to healthcare opportunities globally. The team has global execution capabilities and a strong track record across both M&A and equity offerings, including a market leading global biotech franchise. Jefferies coverage bankers provide in-depth worldwide coverage of all healthcare subsectors, including biotech, medtech, pharmaceuticals, diagnostics, and healthcare services. Managing Directors have an average of 17 years of healthcare investment banking experience.
Suzhou BioBAY is the key driver of life science innovation for Suzhou Industrial Park (SIP). Nearly 500 high-tech innovative companies covering drug discovery, medical device (including IVD), biotech, CRO have been located in BioBAY. More than 10000 scientists and professionals have come to join this dynamic innovative community, including 62 talents of The Recruitment Program of Global Experts.
BioBAY is playing an active role in building an interactive and collaborative innovation ecosystem:
- Cold Spring Harbor Asia Conference Centre — cutting-edge academic resources and global technical communication
- BioTOP — one-stop professional solutions for biomedical companies, including analysis & test, GMP verification, biomaterials trading, training, etc.
- BioBAY Sangtian Island — commercialization base for high-tech drug, medical device and IVD companies
- BioBAY Changshu — top class industrial base for biomedical industry with international advanced standards
6 Dimensions Capital is a leading healthcare focused investment firm with an in-depth focus and extensive coverage across China and the United States. The firm currently has US$1.6 billion assets under management through 4 US dollar-denominated and 3 RMB-denominated funds with offices in Shanghai, Boston, Hong Kong and San Francisco.
6 Dimensions Capital was formed in May 2017 through the merger of Frontline BioVentures and WuXi Healthcare Ventures, two prominent and complementary China-U.S. healthcare investment firms. The merger has created a powerhouse that aims to fund innovation in an optimal position to capture the biggest value appreciation on both sides of the Pacific.
If you’re looking to do business or invest in Canada, the Invest in Canada Bureau global network of professionals can assist foreign companies in making Canada their next investment destination or work with existing investors in Canada in expanding their Canadian operations!
The Invest in Canada Bureau is part of the Canadian Trade Commissioner Service (TCS) which is under the department of Global Affairs Canada (GAC). The TCS helps Canadian companies and organizations succeed globally, and the Invest in Canada Bureau supports foreign investment in Canada. Created in 1894, the TCS has more than 120 years of experience helping Canadian companies succeed in foreign markets by promoting the economic interests of Canada in the global marketplace. Canada’s active and successful participation in the global economy impacts all Canadians. Consider that a fifth of all jobs in this country are directly linked to international trade and Canadians companies are among the most successful on the international stage. The TCS has trade offices across Canada and 161 offices around the world.
Medtronic plc has its principal executive offices in Ireland and continues to be operationally headquartered in Minneapolis. The company is the global leader in medical technology - alleviating pain, restoring health, and extending life for millions of people around the world. Currently Medtronic products and therapies involve multiple business units including cardiac rhythm disease management, coronary, cardiac surgery, endovascular, diabetes, neuromodulation/pain management, spinal and orthopedic, ENT/neurosurgery/navigation, cardiothoracic surgery, urological/urogynecological/gastroenterological, diagnostic solutions, etc. Medtronic has a diversified growth profile and broad geographic reach, with more than 84000 employees in more than 160 countries and areas, reaching $29.7 billion of revenue in FY17. Every one second, somewhere in the world, two lives are saved or improved by a Medtronic product or therapy.
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help improve patient outcomes, improve the safety and efficiency of clinicians’ care delivery process, enable laboratory scientists to better diagnose disease and advance researchers’ capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. In 2017, BD welcomed C. R. Bard and its products into the BD family.
BeiGene is a global, commercial-stage, research-based biotechnology company focused on molecularly targeted and immuno-oncology cancer therapeutics. With a team of over 900 employees in China, the United States, and Australia, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is also working to create combination solutions aimed to have both a meaningful and lasting impact on cancer patients. BeiGene markets ABRAXANE® (nanoparticle albumin–bound paclitaxel), REVLIMID® (lenalidomide), and VIDAZA® (azacitidine) in China under a license from Celgene Corporation.
About Boston Scientific in China
Boston Scientific established its China headquarters in Shanghai in 1997 and now has branches and R&D centers in Beijing, Shanghai and Guangzhou. Core Boston Scientific businesses in China include cardiac intervention, structural heart, cardiac rhythm management, endoscopy, peripheral interventions and oncology, urology and pelvic health, and pulmonary. As an R&D leader, the company provides high performance medical products and solutions for the prevention, diagnosis and treatment of assorted diseases and conditions. Boston Scientific strives to provide the most innovative global medical technology that is custom-tailored to fit the needs of Chinese patients. For more information, visit us at: www.bostonscientific.cn
About Boston Scientific
Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 30 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit www.bostonscientific.com and connect on Twitter and Facebook.
C-Bridge Capital is a healthcare dedicated private equity firm, focused on growth and late stage investment opportunities. C-Bridge Capital’s current portfolio includes China’s leading players in pharmaceuticals, medical devices, diagnostics and healthcare services. C-Bridge Capital is committed to support commercialization of cutting edge technologies and companies that fulfill unmet medical needs, thus continuously improving the standard and quality of care for patients.
Eight Roads Ventures is a global venture capital firm that backs entrepreneurs with aspirations for greatness. It has over 20 years of venture capital experience in China and has supported over 80 companies in the country’s healthcare, enterprise technology and consumer technology sectors. As the proprietary investment arm of Fidelity International Limited, Eight Roads is committed to building bold and meaningful businesses and together with its associated funds manages USD 3.6bn of capital across offices in the China, Japan, UK, India and the US.
Eight Roads Ventures led successful investments in China, including Alibaba, China PnR, Wuxi PharmaTech, Hile, Innovent, Adagene and Hua Medicine. It launched its first USD 250 m China Healthcare Fund in 2017.
GenScript Biotech Corporation (www.genscript.com) is a public company listed in Hong Kong Exchange. GenScript was a pioneer in gene synthesis and synthetic biology. The company is founded in 2002, Its headquarters is located in New Jersey, USA, and it has a subsidiary in Nanjing, China. GenScript is a fast growing company and has grown into more than 1,800 employees. Its main business includes life science research, pre-clinical drug discovery, life science catalogue products, synthetic bio-products, immunotherapy development and so on. Dedicated to its commitment of benefiting all mankind with continuous innovation, Genscript is recognized as a global leader of gene synthesis technology and has served more than 5000 clients from over 100 countries and areas.
Hangzhou Economic and Technological Development Area (HEDA) is a comprehensive development area combining advanced manufacturing park, university town and comprehensive bonded zone. It also serves as one of the sub-centers of Hangzhou. HEDA has been dubbed as the national innovation and entrepreneurship demonstration base, the national demonstration area for quality and safety of imported and exported bio-medicines (biological products), provincial level featured town of Zhejiang, the innovation base for invigorating trade with bio-medical science and technology of Zhejiang Province and the essential area of “New Medicine Port” of Hangzhou. As one of the leading feature industries of HEDA, its biopharm industry production value reached 30 billion Yuan. The growth rate has stayed above 15%. HEDA takes nearly 40% of the biopharm industry gross value of Hangzhou.
As the essential platformof biopharm Industry in HEDA, the Hangzhou Pharma Town is key to the health industry of Hangzhou, aiming to build a full industrial service system, and create an eco-system for development of bio-pharmaceutical industry. The Town will play a leading role for the integrated, concentrated and intensive development of bio-pharmaceutical industry in HEDA. The Town is promoting biopharmaceutical drugs, biomedical engineering and high-tech medical device.
More than 300 biopharm companies have settled in the town, with seven of the top 10 big pharmas have invested in HEDA,Iincluding Pfizer, Merck, Bayer, Gilead, Eli Lilly, Johnson and Johnson, and Abbott. The town has over 100 top talents in biopharm: Members of CAS, Thousand Talents Plan experts of national and provincial levels, and “521” expert of Hangzhou；More than 200 high-tech biopharm companies and more than 200 R&D institutions；More than 20,000 employees engaged in biopharm, including more than 7,000 with bachelor’s degree or a higher degree and more than 2,000 with master’s degree or a higher degree.
In the coming 3 years, The Town is to accumulatively invest more than 10 billion Yuan, to construct 20 programs with investment of more than 100 million Yuan, to bring in 40 top talents of various levels as well as 400 bio-pharmacy enterprises，and the production value of bio-medicine reaching 50 billion Yuan.
Nanjing Legend Biotech Co., Ltd, is a biotechnology company, engaged in the R&D, clinical development of cellular immunotherapy. Currently, 100% of the R&D staff have postgraduate or above degree and over 10% has overseas background.
Nanjing Legend has developed a series of CAR-T products with independent intellectual property to treat refractory blood cancers and solid cancers Legend has its unique strength in the optimization of CAR structures and the development of bispecific CAR-T therapies and has made a remarkable breakthrough in the field.
Legend’s LCAR-B38M CAR-T has demonstrated its high degree of safety and efficacy profile in treating multiple myeloma, which will bring about profound social benefits and huge economic value.
A Legacy of Innovation
MSD has a strong history of success in translating cutting-edge research into life-saving medical breakthroughs. Our scientific advances have made a difference in the lives of millions of patients worldwide. MSD had sales of more than $39 billion in 2016 and we operate in more than 140 countries.
We recognize that building partnerships is one of our most important jobs. We’re interested in any novel approach with robust, scientific data and significant advantages for patients over current therapies — from discovery to late-stage without regard to therapeutic area or modality.
Learn more at msd.com/licensing.
MSD is known as Merck in the United States and Canada.
Established in 1989, OrbiMed is the world’s largest healthcare and life sciences-dedicated investment firm. OrbiMed manages approximately USD$15 billion assets, including several PE/VC funds, hedge funds and mutual funds. Since the inception of its private equity investment activities in 1993, OrbiMed has successfully invested in over 200 private companies across a wide range of therapeutic categories and stages of development, over 100 of which have been either listed or acquired. OrbiMed has continued strong performance in public equity as well. OrbiMed’s investment team includes over 80 experienced professionals with backgrounds in science, medicine, industry, finance and law. OrbiMed Asia, with offices in Shanghai and Mumbai, manages OrbiMed Asia Partners (OAP), the first pan-Asia healthcare and life sciences-dedicated private equity fund. OAP has made PE investments in 29 companies, with close to USD$500 million under management. OrbiMed has also invested over USD$1 billion in the stocks of Asia public healthcare companies.
Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Consumer Healthcare.
Sanofi has a strong commitment to China. In 1982, Sanofi became one of the first foreign pharmaceutical companies to open offices in China. Today, the company has about 9,000 employees in various regions in China, and is one of the pharmaceutical companies with the fastest growth. With Shanghai headquarters in China, Sanofi has 11 branches located in Beijing, Tianjin, Shenyang, Jinan, Hangzhou, Nanjing, Wuhan, Chengdu, Guangzhou, Fujian and Urumchi.
The Shelburne Group advises innovative life sciences and medical technology companies on matters of capital raises, government affairs, and market access. Through roadshows, conferences, and one-on-one meetings The Shelburne Group introduces innovative companies to a broad network of stakeholders in Asia Pacific specializing in constructive cross-border partnerships.
Zai Lab (NASDAQ: ZLAB) is a Shanghai-based innovative biopharmaceutical company focused on bringing transformative medicines for cancer, autoimmune and infectious diseases to patients in China and around the world. The company’s experienced team has secured partnerships with leading global biopharma companies, generating a broad pipeline of innovative drug candidates targeting the fast growing segments of China’s pharmaceutical market and global unmet medical needs. Zai Lab’s vision is to become a fully integrated biopharmaceutical company, discovering, developing, manufacturing and commercializing its partner’s and its own products in order to impact human health worldwide.
BayHelix Group is a non-profit, invitation-only organization of business leaders of Chinese heritage that fosters the growth of the life sciences and healthcare industry around the Pacific Rim and beyond. Founded in 2001, BayHelix has grown to over 300 members throughout the U.S., Canada, and Greater China. The membership base covers virtually all of the world’s top pharmaceutical and biopharmaceutical companies, as well as leading services and investment firms. Over one third of the members are senior executives, over 80% have PhDs in the life sciences, and nearly half have MBAs from the leading business schools in U.S.
Our mission is simple: create the best, most innovative events to provide you with the latest business information and the greatest opportunity to network with your peers and new potential business partners.
Since 2008, Lychee Group has helped launch some of the longest running and most reputable life sciences conferences in China including: ChinaTrials: Clinical Development Leaders' Summit, China Healthcare Investment Conference (CHIC), China Medical Affairs Summit, DeviceChina, BioCentury's China Healthcare Summit and Healthcare Capital & Connections Summit (HCCS).
Founded by industry-recognized editors, RNDer and PharmaDJ are the leading publications providing value-added analysis for pharmaceutical and biotechnology companies doing business in China. With a mission to facilitate drug R&D and regulatory science in China, we talk to regulators and key opinion leaders from industry to piece together the China market puzzle for our readers.
Since its founding in 2007, ChinaBio® Group has created a broad platform of capabilities connecting China life science with the world. ChinaBio has helped western life science companies identify over 400 licensing and acquisition opportunities and raise over USD 500 million in funding in China.
Conferences: ChinaBio organizes the premier life science investment and partnering conferences in China, having attracted over 5,000 attendees.
Consulting: ChinaBio helps global life science companies to define and execute a successful strategy in China.
Capital: ChinaBio launched its first VC fund in 2014 focused on bringing Western companies and technologies to China.
Publishing: ChinaBio® Today is the most widely read online and email newsletter on China's life science industry, with over 18,000 readers.
BioCentury and BayHelix Present: The 5th China Healthcare Summit. The China Summit is a VIP-only event for busy biopharma and life sciences executives and investors to get a first-hand look at the innovation, business and policy transformations taking place in China. The conference is THE place to meet the right Chinese investors and partners in an intimate setting. The China Summit will include:
-Two days of strategic sessions and keynotes tailored to help executives understand emerging opportunities and challenges in China.
-The China Summit report created by Insights Partner, McKinsey & Company. This exclusive analysis documents market trends and identifies business imperatives for biopharma and life sciences companies doing business in China.
-New for 2018: For the 1st time, the China Summit will feature a presenting company track to showcase biotechs from China, Asia and the West, hand-picked by BioCentury and BayHelix.
-New for 2018: A 1x1 meeting system will allow attendees to arrange face-to-face discussions with investors and corporate delegates.
-Three VIP receptions to network with senior-level executives and investors.
-The annual BayHelix Awards ceremony and lunch to celebrate R&D and commercial achievements in China.
-Multiple networking breaks throughout the event to meet peers across the China innovation ecosystem.
The China Summit agenda has been developed by an Organizing Committee that includes China industry KOLs and BioCentury's editorial team. Simultaneous translation is provided in all strategic sessions.
BioCentury is the essential source of intelligence for a global audience of biotech and pharmaceutical company professionals, investors, researchers, service providers and industry stakeholders who demand deep industry knowledge, data-driven analysis, independent perspective and a commitment to accuracy. Our insight, trusted reporting and in-depth analysis are built on independent, objective surveillance of the biotechnology sector, producing the industry's most respected journals and data solution resources, since 1993.
For more than 50 years, DIA (the Drug Information Association), a non-profit association, has served as a global forum for all those involved in health care product development and life cycle management to exchange knowledge and collaborate in a neutral setting, and a unbiased forum for the exchange of information across multiple disciplines of programming and publications.
Founded in 2002, GBI (www.gbihealth.com) is an information, applications and services company focused on the healthcare industry. It boasts a diverse portfolio of marketing intelligence solutions that enable organizations and individuals to make data-driven decisions and communicate more effectively. Over 15 years of development, GBI has built a global presence with around 200 staff across four locations in Shanghai, Beijing, São Paolo, and Washington, DC. Our first database product was launched in 2009, and we have now built a portfolio based around the flagship brands of SOURCE, DEVINT, METRIX and NAVIS, covering the markets of China, Latin America, and the United States. GBI is now a trusted provider for the pharmaceutical and medtech industries, with established long-term partnerships with multinational industry players.
GlobalData is a leading intelligence data and analysis company, serving over 4,000 world’s largest companies to do strategic planning and market development. We help our client make better decisions by gaining insights into competitors, evaluating market size and attaining strategic KOL insights and analysis in both pharma and medical device markets with our fully integrated intelligence centers.
Lingmed promotes three leading intelligence databases for healthcare professionals in China to make better decisions. In addition, we together with our partners in Europe provide partnering services to bridge European and Chinese pharmaceuticals with biotech companies, including valuation and market monitoring reports.
The New Drug Founders Club was founded in April, 2015, to form a network for founders of companies focusing on innovative new drug R&D and of companies providing relevant services. The club is highly prestigious in that only founders of such companies and people well-recognized for having special and major contributions to new drug R&D in China (including China R&D heads of multinational companies, R&D heads of major domestic companies, partners of VC, and other nationally recognized leaders in new drug R&D) can be admitted to the club. This feature distinguish this club from any other professional organizations in China or the world. Currently there are about 209 members in the club, with several new applications reviewed for approval every month.
China’s biotech scene has been exploding over the past 2 years. Chinese investors are not just pouring billions into new Asian startups, they’re also jumping into global syndicates backing a new generation of startups in the US and Europe as well.
This October, we’ll be bringing top industry players in China and the US to Shanghai for the inaugural run of the US-China Biopharma Innovation and Investment Summit. For US companies, this is a chance to explore the most important emerging healthcare market in the world, with a forecast on drug innovation and a chance to meet potential partners. And you’ll hear directly from a group of headliners on both sides of the Pacific on the most important developments you need to be aware of, with a special focus on the regulatory scene.
This is a crucial year for US-China biopharma and you won't want to miss this 2-day summit we're planning for you at the Shanghai Four Seasons, located in Pudong in the ultra-modern 21st Century Tower.